Search Results 2311-2320 of 21862 for platelets

1. A Clinical Study Of KTX-2001 In Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)

   Adequate hematological function (neutrophils >1 × 109/L, platelet count >100 × 109/L, hemoglobin >9 g/dL) with no prior transfusions within 2 weeks.

2. Z-Endoxifen Hydrochloride in Treating Patients with Metastatic or Locally Recurrent Estrogen Receptor-Positive Breast Cancer - Mayo Clinic

   Platelet count ≥ 75,000/uL; Total bilirubin ≤ 1.5 times institutional upper limit of normal (IULN); Aspartate aminotransferase (AST) (serum glutamic ...

3. A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies - Mayo Clinic

   Platelets ≥ 100 x 109/L; Life expectancy ≥ 3 months. Exclusion Criteria: Anti-cancer chemotherapy, radiotherapy, immunotherapy, or investigational agents ...

4. A Phase 1-2 Multi-Center Study Evaluating Axicabtagene Ciloleucel in Subjects With Refractory Aggressive Non-Hodgkin Lymphoma (ZUMA-1) - Mayo Clinic

   Platelet count ≥ 75,000/uL. Absolute lymphocyte count ≥ 100/uL. Adequate renal, hepatic, pulmonary and cardiac function defined as: Creatinine clearance ...

5. Low-Dose or High-Dose Lenalidomide in Treating Children with Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma - Mayo Clinic

   Platelet count ≥ 100,000/uL (transfusion independent); Hemoglobin ≥ 8.0 g/dL (may receive red blood cell [RBC] transfusions); Creatinine clearance or ...

6. Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for Chemotherapy - Mayo Clinic

   Absolute neutrophil count ≥ 1,500/mcl · Platelets ≥ 100,000/mcl · Hemoglobin ≥ 9.0 g/dL · PT or INR ≤ 1.2 x IULN (if not receiving anticoagulation therapy) ...

7. Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia - Mayo Clinic

   More than 4 days since prior growth factors that support platelet or white cell number or function; No concurrent enzyme-inducing anticonvulsant medications ...

8. An Efficacy Study Comparing Oral Ixazomib/Dexamethasone and Oral Pomalidomide/Dexamethasone in Relapsed and/or Refractory Multiple Myeloma - Mayo Clinic

   Participation eligibility · Absolute neutrophil count (ANC) ≥1000/mm3 and platelet count ≥75,000/mm3, without growth factor or transfusion support; · Total ...

9. Study to Investigate the Safety and Effectiveness of Two Doses of the Antibody Drug GSK2857916 in Relapsed/Refractory Multiple Myeloma Patients - Mayo Clinic

   Platelets>= 50 X 10^9/L;; Total bilirubin <=1.5X Upper limit of normal (ULN). Isolated bilirubin >=1.5xULN is acceptable if bilirubin is fractionated and ...

10. COlorectal Cancer Treated With Adjuvant Regorafenib Versus Placebo After Curative Treatment of Liver Metastases in a Randomized, Double-blind, Placebo‑Controlled Phase-III STudy - Mayo Clinic

    Platelet count ≥ 100,000 /mm3, hemoglobin ≥ 9 g/dL, absolute neutrophil count ≥ 1500/mm3 without transfusions or granulocyte colony stimulating factor ...